To prepare:

Review your state’s process for obtaining prescriptive authority and associated fees (Georgia)

Review the DEA website and review the process for obtaining a DEA number and associated fees.

Review and select one of the following case studies and analyze the provider information:

Case Study One: Lori, FNP-BC, is a new graduate and has recently passed her certification exam. She has just been hired to work for a Primary Care Clinic as a nurse practitioner in a small town. She will be working with one physician at one site.

Case study Two: James, FNP-BC, works with a physician who specializes in pain control. He works in several clinics in the large urban city where he practices as nurse practitioner.

Write 1 to 2 pages

Post a brief summary of the case study you selected and an explanation of the appropriate prescriptive authority and DEA registration process needed for the case study you selected. Then, explain the safe prescribing practices that these providers should use for these settings.

Reference

Buppert, C. (2015). Prescribing. In Nurse Practitioner’s Business Practice and Legal Guide (5th ed.). (199-204). Burlington, MA: Jones & Bartlett.

 U.S. Department of Justice (n.d.). Drug Enforcement Administration: Office of Diversion Control. Retrieved from http://https://www.dea.gov/ops/diversion.shtml

Required Media

Fisher, A. S. (2015, June 5). Medical Records: What Must Be Included from a Legal Standpoint? [Video file]. Retrieved from https://www.youtube.com/watch?v=euhoL62YsSk

 

"Not answered?"

Question 1

1. In environmental health, the term toxin refers to a toxic substance that _______________.

[removed]		is naturally produced by a plant or animal
[removed]		occurs in the occupational setting
[removed]		results from human activity
[removed]		a man-made product introduced into the environment due to human activity

1 points  

Question 2

1. In toxicity testing in rodents, the LD50 is a dose that is _______________.

[removed]		acutely fatal to 50 percent of test animals
[removed]		fatal to 50 percent of test animals within a 90-day period
[removed]		fatal to 50 percent of test animals after lifetime bioaccumulation

1 points  

Question 3

1. Which of the following is not characteristic of a health impact assessment?

[removed]		It evaluates a site or activity as it is, rather than looking forward in time
[removed]		It includes social and economic factors in the assessment
[removed]		It incorporates input from community members

1 points  

Question 4

1. An exposure pathway connects _______________ to _______________.

[removed]		an exposure / a change in tissue structure or function
[removed]		inhalation / absorption
[removed]		the environmental source of a contaminant / the point of exposure

1 points  

Question 5

1. The three major routes of human exposure to environmental contaminants are _______________.

[removed]		by air, water, and soil
[removed]		environmental, occupational, and residential
[removed]		ingestion, inhalation, and dermal contact

1 points  

Question 6

1. The phrase contact with the human envelope is a common definition of _______________.

[removed]		absorption
[removed]		disposition
[removed]		exposure

1 points  

Question 7

1. The quantity of a toxicant (or its breakdown product) that is available to interact with some vulnerable tissue in the body is called the _______________.

[removed]		absorbed dose
[removed]		biologically effective dose
[removed]		body burden

1 points  

Question 8

1. The body burden of a chemical in the body reflects the net effect of _______________.

[removed]		absorption and biological effectiveness
[removed]		synergism and antagonism
[removed]		the processes of toxicokinetics

1 points  

Question 9

1. Bioaccumulation is the _______________.

[removed]		gradual building up of a chemical in the tissue of an organism
[removed]		increase of concentrations of a chemical at higher levels of a food pyramid
[removed]		movement of a chemical from water to living tissue

1 points  

Question 10

1. Which of the following is an example of a biomarker?

[removed]		Body mass index calculated from measured height and weight
[removed]		Concentration of a pesticide in blood
[removed]		Inhalation rate in liters per hour

1 points  

Question 11

1. The Ames test is a test of a chemical’s _______________.

[removed]		acute lethality, and is conducted in rodents
[removed]		mutagenicity, and is conducted in bacteria
[removed]		teratogenic potential, and is conducted mammalian cells

1 points  

Question 12

1. Exposure modeling is used to estimate the _______________.

[removed]		biologically effective dose of a toxicant
[removed]		fate and transport of a toxicant
[removed]		ingestion of, inhalation of, or dermal contact with a toxicant

1 points  

Question 13

1. Conceptually, a reference dose is a dose that has no adverse effects in _______________.

[removed]		sensitive subpopulations over a long-term exposure
[removed]		sensitive subpopulations over a short-term exposure
[removed]		the general population over a long-term exposure
[removed]		the general population over a short-term exposure

1 points  

Question 14

1. Which of the following is one of the major processes which together make up toxicokinetics?

[removed]		Bioconcentration
[removed]		Distribution
[removed]		Mutation
[removed]		Synergism

1 points  

Question 15

1. In doing a risk assessment for a chemical, the usual assumption is that _______________.

[removed]		carcinogenicity has a threshold; non-cancer effects do not
[removed]		non-cancer effects have a threshold; carcinogenicity does not
[removed]		both carcinogenicity and non-cancer effects have thresholds
[removed]		neither carcinogenicity nor non-cancer effects has a threshold

1 points  

Click Save and Submit to save and submit. Click Save All Answers to save all answers.

 

"Not answered?"